Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group Viewpoint.
Cladribine tablets
Disease activity
Multiple sclerosis
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
13
05
2023
accepted:
23
06
2023
revised:
22
06
2023
pubmed:
12
7
2023
medline:
12
7
2023
entrez:
12
7
2023
Statut:
ppublish
Résumé
Cladribine tablets (Mavenclad
Identifiants
pubmed: 37436562
doi: 10.1007/s00415-023-11846-4
pii: 10.1007/s00415-023-11846-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5188-5195Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Meuth SG, Bayas A, Kallmann B, Linker R, Rieckmann P, Wattjes MP, Mäurer M, Kleinschnitz C (2022) Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Expert Opin Pharmacother 23:1503–1510. https://doi.org/10.1080/14656566.2022.2106783
doi: 10.1080/14656566.2022.2106783
pubmed: 35930260
Magalashvili D, Mandel M, Dreyer-Alster S, Didikin M, Harari G, Flechter S, Achiron A (2022) Cladribine treatment for highly active multiple sclerosis: real-world clinical outcomes for years 3 and 4. J Neuroimmunol 372:577966. https://doi.org/10.1016/j.jneuroim.2022.577966
doi: 10.1016/j.jneuroim.2022.577966
pubmed: 36162338
Meca-Lallana V, García Domínguez JM, López Ruiz R, Martín-Martínez J, Arés Luque A, Hernández Pérez MA, Prieto González JM, Landete Pascual L, Sastre-Garriga J (2022) Expert-agreed practical recommendations on the use of cladribine. Neurol Ther 11:1475–1488. https://doi.org/10.1007/s40120-022-00394-0
doi: 10.1007/s40120-022-00394-0
pubmed: 36068429
pmcid: 9447968
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B et al (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362:416–426. https://doi.org/10.1056/NEJMoa0902533
doi: 10.1056/NEJMoa0902533
pubmed: 20089960
Oreja-Guevara C, Brownlee W, Celius EG, Centonze D, Giovannoni G, Hodgkinson S, Kleinschnitz C, Havrdova EK, Magyari M, Selchen D et al (2023) Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence. Mult Scler Relat Disord 69:104459. https://doi.org/10.1016/j.msard.2022.104459
doi: 10.1016/j.msard.2022.104459
pubmed: 36565573
Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P (2018) Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler 24:1594–1604. https://doi.org/10.1177/1352458517727603
doi: 10.1177/1352458517727603
pubmed: 28870107
Habek M, Drulovic J, Brecl Jakob G, Barbov I, Radulovic L, Rajda C, Rejdak K, Turčáni P (2023) Treatment with cladribine tablets beyond year 4: a position statement by southeast european multiple sclerosis centers. Neurol Ther 12:25–37. https://doi.org/10.1007/s40120-022-00422-z
doi: 10.1007/s40120-022-00422-z
pubmed: 36394714